CJC-1295 DAC is a lab-made copy of GHRH 1-29 (growth hormone-releasing hormone, the brain signal that tells the pituitary (the master hormone gland at the base of the brain) gland to release growth hormone), changed at four amino acids (Ala2, Gln8, Ala15, Leu27) so the enzyme DPP-IV, which normally chops up GHRH, breaks it down more slowly. The Drug Affinity Complex (DAC) is an added chemical tag (a maleimidopropionyl lysine group) at the end of the peptide. In the body it permanently attaches to the Cys34 spot on serum albumin (the main protein carried in blood). This stretches the half-life (the time for half the drug to leave the body) from minutes for natural GHRH to 5.8-8.1 days. The drug switches on GHRH receptors (GHRHR) on somatotroph cells (growth-hormone-making cells) in the anterior pituitary (the front part of the pituitary gland at the base of the brain). This activates the Gs protein and adenylyl cyclase (an enzyme), raises intracellular cAMP (an internal messenger), and boosts growth hormone gene activity and release. The steady activation keeps growth hormone raised and then raises IGF-1 (a growth signal your liver releases in response to growth hormone) made by the liver. This steady pattern differs from the body's natural pulses of growth hormone, and may cause receptor downregulation (receptors becoming less responsive) with long-term use.